SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia

Solid Biosciences Inc. (SLDB) announced that the FDA has cleared its investigational new drug (IND) application to begin clinical studies on its novel AAV-based gene therapy candidate, SGT-212, for the treatment of Friedreich’s ataxia (FA).Per the company, SGT-212 is the only full-length frataxin replacement gene therapy candidate that targets the cardiac manifestations of FA.SGT-212 is being developed to treat the neurologic and systemic clinical manifestations of FA to address the full spectrum of disease ...